In a major Phase 3 clinical trial, lecanemab showed it could slow the decline in memory and thinking ability by 27% overall ...

Clinical trial of people destined to develop early-onset Alzheimer’s disease shows eliminating amyloid from brain.

Scientists report long-term gantenerumab use might prevent cognitive decline in people with genetic predisposition to ...

A long-term human trial has found that a discontinued drug halved the presentation of early-onset Alzheimer's disease in ...

While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a new study. The ...

Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

Investigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing symptoms by 50%.

Research announced today is the first of its kind to suggest that anti-amyloid drugs can delay or even stop the progression of symptoms in people with early-onset Alzheimer's.

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in ...

Utah State University's ADRC awarded ten grants to support a range of Alzheimer's and dementia research projects.

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...